Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

1310726-59-0Upadacitinib Enantiomer Impurity

● In Stock

Catalogue No.:	VE0027850
CAS No.:	1310726-59-0
Mol. Formula:	C17H19F3N6O
Mol. Weight:	380.38 g/mol

Request a quote

Add to RFQ list

Additional information on CAS 1310726-59-0

Parent drug

Upadacitinib

IUPAC Name

(3R,4S)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

Pharmacopeial Synonyms

N/A

Synonyms

N/A

Smiles

O=C(N1C[C@H](CC)[C@H](C2=CN=C3C=NC(NC=C4)=C4N32)C1)NCC(F)(F)F

InChI

InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m0/s1

Description

Upadacitinib Enantiomer Impurity (CAS 1310726-59-0) is the chiral counter enantiomer encountered during synthesis and resolution of upadacitinib. Monitoring this enantiomeric impurity is essential to ensure stereochemical purity and compliance with regulatory impurity limits. Analytical characterization commonly employs chiral high-performance liquid chromatography, chiroptical methods, polarimetry, nuclear magnetic resonance and mass spectrometry to determine enantiomeric excess, confirm structure and achieve trace level quantitation. Stability assessment and process development address potential racemization pathways, while control strategies including in-process controls, validated assays and defined specification limits mitigate risk to pharmaceutical quality in line with ICH impurity guidance.